Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Alterity Therapeutics Ltd
ATHECurrent price
1.61 USD
0 USD (0.00%)
Last closed
1.6 USD
Company
alteritytherapeutics.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
17 618 040 USD
Yield for 12 month
-43.31 %
1Y
3Y
5Y
10Y
15Y
ATHE
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Address: 350 Collins Street, Melbourne, VIC, Australia, 3000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7 USDP/E ratio
–Dividend Yield
–Current Year
+1 730 671 USD
Last Year
+2 346 992 USD
Current Quarter
–
Last Quarter
–
Current Year
+1 662 821 USD
Last Year
+2 179 947 USD
Current Quarter
–
Last Quarter
–
Key Figures ATHE
1 year
3 years
5 years
10 years
EBITDA
-12 832 270 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-28.94 %
PEG Ratio
–
Return On Equity TTM
-53.72 %
Wall Street Target Price
7 USD
Revenue TTM
3 431 217 USD
Book Value
0.006 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-20.3 %
Dividend Yield
–
Gross Profit TTM
3 631 266 USD
Earnings per share
-1.67 USD
Diluted Eps TTM
-1.67 USD
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ATHE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATHE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
09.01.2023
Dividend Date
–
Stock Valuation ATHE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
113.9898
Price Sales TTM
7.4802
Enterprise Value EBITDA
-0.728
Price Book MRQ
1.7291
Financials ATHE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ATHE
For 52 weeks
1.55 USD
5.41 USD
50 Day MA
1.92 USD
Shares Short Prior Month
22 478
200 Day MA
2.12 USD
Short Ratio
1.01
Shares Short
13 371
Short Percent
2.25 %
BeatStart